Anti-CLDN18.2 monoclonal antibodies and uses thereof
High-affinity humanized monoclonal antibodies targeting CLDN18.2 are developed with specific CDRs and framework regions, addressing the challenge of similarity and immune tolerance, showing superior tumor suppression efficacy.
Patent Information
- Application Number
- JP2024527759
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-11
- Filing Date
- 2022-11-11
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2042-11-11
AI Technical Summary
The development of high affinity and high bioactivity CLDN18.2 antibodies is hindered by the high similarity between human CLDN18.1 and CLDN18.2, and the need to overcome immune tolerance in mouse models for antibody screening.
The development of anti-CLDN18.2 antibodies with specific complementarity determining regions (CDRs) and framework regions, combined with human IgG1 and kappa/lambda constant regions, to create high-affinity humanized monoclonal antibodies that specifically target CLDN18.2.
The antibodies exhibit enhanced binding, ADCC, CDC, and antiproliferative activities against tumor cells, demonstrating significant tumor growth inhibition in nude mice models, with improved biological activity compared to chimeric antibodies.
Smart Images

Figure 2024544961000020 
Figure 2024544961000021 
Figure 2024544961000022
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of medicine, specifically to an anti-CLDN18.2 humanized monoclonal antibody and its formulation. [Background technology]
[0002] Tight junctions (TJs) are multi-molecular complexes that regulate the permeability between epithelial cells. In the tight junction complexes, claudins form tight channels between adjacent cells and regulate the flow of ions, solutes, and other substances.
[0003] CLDN18 is a major component of tight junctions in lung and gastric epithelial cells, and CLDN18 has two subtypes, CLDN18.1 and CLDN18.2, of which CLDN18.1 is mainly expressed in the lung and CLDN18.2 mainly in the stomach.
[0004] Studies have shown that CLDN18.2 is highly expressed in many tumors, including primary and metastatic gastric cancer, pancreatic cancer, esophageal cancer, lung cancer, bile duct cancer, and ovarian cancer (Sahin U et al., Clin Cancer Res, 2008;14(23):7624-34). Tumor cells lose the tight junction structure due to their rapid proliferation, invasiveness, and metastasis, making CLDN18.2 molecules on their surface more easily exposed, making CLDN18.2 an ideal target for tumor therapy (Hewitt KJ et al., BMC Cancer, 2006;6:186).
[0005] IMAB362, a chimeric antibody against CLDN18.2 developed by Ganymed Pharmaceuticals AG, has already entered a phase III clinical study. In a phase II clinical study of late-stage or recurrent gastroesophageal cancer, IMAB362 significantly extended patients' PFS and OS when administered alone rather than in combination with the first-line chemotherapy drug EOX (epirubicin, oxaliplatin, capecitabine), making it a potential drug for the treatment of diseases such as gastric cancer and esophageal cancer (Lordick F et al., Gastric Cancer, 2021; 24(3): 721-730.).
[0006] Due to the potential of CLDN18.2 in tumor therapy, there is great clinical demand for the development of highly active antibody drugs.
[0007] The high similarity between human CLDN18.1 and CLDN18.2 poses a challenge to the development of CLDN18.2-specific antibodies. Moreover, mouse CLDN18.2 has a completely identical sequence to the extracellular loop 1 of human CLDN18.2, so screening for specific anti-human CLDN18.2 antibodies in mice must overcome the immune resistance of mice. Therefore, the development of a drug that specifically recognizes human CLDN18.2 antibodies with high activity requires overcoming many technical difficulties.
[0008] Therefore, there remains a need in the art for the development of high affinity and high biological activity CLDN18.2 antibodies and uses thereof. Summary of the Invention [Problem to be solved by the invention]
[0009] It is an object of the present invention to provide high affinity and high biological activity CLDN18.2 antibodies and uses thereof. [Means for solving the problem]
[0010] In a first aspect of the invention, there is provided a heavy chain variable region of an antibody, the heavy chain variable region comprising the following three complementarity determining regions CDRs: (1) a complementarity determining region CDR1, whose amino acid sequence is shown in SEQ ID NO:3; (2) a complementarity determining region CDR2 having an amino acid sequence as set forth in SEQ ID NO: 4 or 16; and (3) A complementarity determining region CDR3 having an amino acid sequence shown in SEQ ID NO: 5 or 17.
[0011] In another preferred embodiment, the sequences of the three complementarity determining regions CDRs of the heavy chain variable region are SEQ ID NOs: 3, 4 and 5; or 3, 16 and 5; or 3, 4 and 17.
[0012] In another preferred embodiment, the heavy chain variable region comprises the following four framework regions FR, wherein the four framework regions FR are derived from the four framework regions FR corresponding to SEQ ID NOs: 1, 11, 12 and 13: In another preferred embodiment, the heavy chain variable region has the amino acid sequence set forth in SEQ ID NO:1, 11, 12 or 13.
[0013] In a second aspect of the invention, there is provided an antibody heavy chain having a heavy chain variable region of an antibody according to the first aspect of the invention. In another preferred embodiment, the constant region of the heavy chain is of human origin. In another preferred embodiment, the heavy chain constant region is a heavy chain constant region of human IgG1, IgG2, or the like.
[0014] In a third aspect of the invention there is provided an antibody light chain variable region comprising the following three complementarity determining regions CDR': (1) a complementarity determining region CDR1', the amino acid sequence of which is shown in SEQ ID NO:8; (2) a complementarity determining region CDR2', the amino acid sequence of which is shown in SEQ ID NO:9; and (3) A complementarity determining region CDR3', the amino acid sequence of which is shown in SEQ ID NO:10.
[0015] In another preferred embodiment, the light chain variable region comprises the following four framework regions FR, wherein the four framework regions FR are derived from the four framework regions FR corresponding to SEQ ID NOs: 6, 14, and 15: In another preferred embodiment, the light chain variable region has the amino acid sequence set forth in SEQ ID NO:6, 14, or 15.
[0016] In a fourth aspect of the invention, there is provided an antibody light chain having a light chain variable region of an antibody according to the third aspect of the invention. In another preferred embodiment, the constant region of the light chain is of human origin. In another preferred embodiment, the light chain constant region is a human κ, λ or other light chain constant region.
[0017] In a fifth aspect of the present invention, (1) a heavy chain variable region according to the first aspect of the invention, and / or (2) A light chain variable region according to the third aspect of the present invention. or having a heavy chain according to the second aspect of the invention, and / or a light chain according to the fourth aspect of the invention.
[0018] In another preferred embodiment, the antibody further comprises a heavy chain constant region and a light chain constant region. In another preferred embodiment, the antibody has a heavy chain variable region as shown in SEQ ID NO:1, 11, 12 or 13, and / or a light chain variable region as shown in SEQ ID NO:6, 14, and 15. In another preferred embodiment, the antibody has a heavy chain variable region set forth in SEQ ID NO:1, 11, 12 or 13, and / or a light chain variable region set forth in SEQ ID NO:15.
[0019] In another preferred embodiment, the antibody is selected from the following group: (Z1) an antibody having a heavy chain variable region represented by SEQ ID NO: 1 and a light chain variable region represented by SEQ ID NO: 6; (Z2) an antibody having a heavy chain variable region represented by SEQ ID NO: 11 and a light chain variable region represented by SEQ ID NO: 14; (Z3) an antibody having a heavy chain variable region represented by SEQ ID NO: 11 and a light chain variable region represented by SEQ ID NO: 15; (Z4) An antibody having a heavy chain variable region represented by SEQ ID NO: 12 and a light chain variable region represented by SEQ ID NO: 14; (Z5) an antibody having a heavy chain variable region set forth in SEQ ID NO: 12 and a light chain variable region set forth in SEQ ID NO: 15; (Z6) An antibody having a heavy chain variable region represented by SEQ ID NO: 13 and a light chain variable region represented by SEQ ID NO: 14; (Z7) An antibody having a heavy chain variable region shown in SEQ ID NO: 13 and a light chain variable region shown in SEQ ID NO: 15.
[0020] In another preferred embodiment, the heavy chain of the antibody has the amino acid sequence shown in SEQ ID NO: 18, 20, 21 or 22. In another preferred embodiment, the light chain of the antibody has the amino acid sequence set forth in SEQ ID NO:19. In another preferred embodiment, the antibody is a humanized antibody.
[0021] In another preferred embodiment, the antibody specifically binds to CLDN18.2. In another preferred embodiment, the antibody is a double-chain antibody or a single-chain antibody. In another preferred embodiment, the antibody is a monoclonal antibody.
[0022] In another preferred embodiment, the antibody is a bispecific antibody. In another preferred embodiment, the antibody is in the form of a drug conjugate. The present invention also provides an antibody corresponding to 624, which has a heavy chain variable region shown in SEQ ID NO:23 and a light chain variable region shown in SEQ ID NO:24.
[0023] In a sixth aspect of the present invention there is provided a recombinant protein comprising: (i) a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention, and (ii) an optional tag sequence to aid in expression and / or purification; The present invention provides a protein having the formula:
[0024] In another preferred embodiment, the tag sequence comprises a 6His tag. In another preferred embodiment, the recombinant protein (or polypeptide) comprises a fusion protein. In another preferred embodiment, the recombinant protein is a monomer, dimer, or multimer.
[0025] In a seventh aspect of the invention, there is provided an antibody formulation comprising: (a) an antibody according to the fifth aspect of the invention, and (b) a vehicle comprising a buffer, sterile water, and optionally a surfactant; The present invention provides a formulation comprising:
[0026] In another preferred embodiment, the antibody in the formulation has a concentration of 5-100 mg / mL, preferably 10-70 mg / mL, more preferably 20-60 mg / mL. In another preferred embodiment, the buffer is selected from the group consisting of a citrate buffer system, a histidine buffer system, or a combination thereof.
[0027] In another preferred embodiment, the pH range of the formulation is 5.0-7.5, preferably 5.5-7. In another preferred embodiment, the formulation is an injectable formulation.
[0028] In an eighth aspect of the invention, there is provided a kit comprising an antibody formulation according to the seventh aspect of the invention, as well as a container containing the antibody formulation.
[0029] In a ninth aspect of the invention, there is provided a CAR construct, wherein an scFv fragment of an antigen binding region of the CAR construct is a binding region that specifically binds to CLDN18.2, and the scFv has a heavy chain variable region described in the first aspect of the invention and a light chain variable region described in the third aspect of the invention.
[0030] In a tenth aspect of the invention, there is provided a recombinant immune cell, the immune cell expressing an exogenous CAR construct according to the ninth aspect of the invention. In another preferred embodiment, the immune cells are selected from the group consisting of NK cells and T cells. In another preferred embodiment, the immune cells are from a human or non-human mammal (eg, mouse).
[0031] In an eleventh aspect of the present invention, there is provided an antibody-drug conjugate comprising: (a) an antibody portion selected from the group consisting of a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention, or a combination thereof; (b) a conjugate moiety conjugated to said antibody moiety, said conjugate moiety being selected from the group consisting of a detectable marker, a drug, a toxin, a cytokine, a radionuclide, an enzyme, or a combination thereof; The present invention provides a complex comprising: In another preferred embodiment, the antibody moiety and the conjugate moiety are conjugated via a chemical bond or linker.
[0032] In a twelfth aspect of the invention there is provided the use of an active ingredient selected from the group consisting of a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention, a recombinant protein according to the sixth aspect of the invention, an immune cell according to the tenth aspect of the invention, an antibody-drug conjugate according to the eleventh aspect of the invention, or a combination thereof, wherein the active ingredient is (a) Manufacturing of detection reagents or kits; (b) the manufacture of drugs or preparations for preventing and / or treating CLDN18.2-related diseases; and / or (c) Manufacture of drugs or preparations for preventing and / or treating cancer or tumors The present invention provides a method for the use of the present invention.
[0033] In another preferred embodiment, the tumor is selected from the group consisting of a hematological tumor, a solid tumor, or a combination thereof. In another preferred embodiment, the hematological tumor is selected from the group consisting of acute myeloid leukemia (AML), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma, or a combination thereof.
[0034] In another preferred embodiment, the solid tumor is selected from the group consisting of gastric cancer, gastric cancer peritoneal metastasis, liver cancer, leukemia, kidney tumor, lung cancer, small intestine cancer, bone cancer, prostate cancer, colorectal cancer, breast cancer, colon cancer, cervical cancer, ovarian cancer, lymphatic cancer, nasopharyngeal cancer, adrenal tumor, bladder tumor, non-small cell lung cancer (NSCLC), brain glioma, endometrial cancer, or the like. In another preferred embodiment, the tumor is a tumor with high expression of CLDN18.2.
[0035] In another preferred embodiment, the medicament or preparation is for the manufacture of a medicament or preparation for preventing and / or treating a disease associated with CLDN18.2 (positive expression). In another preferred embodiment, the antibody is in the form of an antibody-drug conjugate (ADC).
[0036] In another preferred embodiment, the detection reagent or kit is for diagnosing a CLDN18.2-related disease. In another preferred embodiment, the detection reagent or kit is for the detection of CLDN18.2 protein in a sample. In another preferred embodiment, the detection reagent is a detection sheet.
[0037] In a thirteenth aspect of the present invention, there is provided a pharmaceutical composition comprising: (i) an active ingredient selected from the group consisting of a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention, a recombinant protein according to the sixth aspect of the invention, an immune cell according to the tenth aspect of the invention, an antibody-drug conjugate according to the eleventh aspect of the invention, or a combination thereof; (ii) a pharma- ceutically acceptable carrier; A composition comprising:
[0038] In another preferred embodiment, the pharmaceutical composition further comprises a second antitumor active ingredient. In another preferred embodiment, the second active ingredient is selected from the group consisting of a cytotoxic drug, a toxin, a cytokine, an enzyme, an antibody, or a combination thereof. In another preferred embodiment, the second active ingredient comprises an antibody targeting EGFR and an antibody targeting HER2.
[0039] In another preferred embodiment, the pharmaceutical composition is a liquid formulation. In another preferred embodiment, the pharmaceutical composition is an injection. In another preferred embodiment, the pharmaceutical composition is used for treating tumors. In another preferred embodiment, the tumor is a tumor with high expression of CLDN18.2.
[0040] In a fourteenth aspect of the present invention, there is provided a polynucleotide encoding a polypeptide selected from the group consisting of: (1) a heavy chain variable region according to the first aspect of the invention, a heavy chain according to the second aspect of the invention, a light chain variable region according to the third aspect of the invention, a light chain according to the fourth aspect of the invention, or an antibody according to the fifth aspect of the invention; or (2) a recombinant protein according to the sixth aspect of the invention, and / or (3) A CAR construct described in the ninth aspect of the present invention.
[0041] In a fifteenth aspect of the invention there is provided a vector comprising a polynucleotide according to the fourteenth aspect of the invention. In another preferred embodiment, the vector comprises a bacterial plasmid, a phage, a yeast plasmid, a plant cell virus, a mammalian cell virus, such as an adenovirus, a retrovirus, or other vector.
[0042] In a sixteenth aspect of the present invention there is provided a genetically engineered host cell which comprises a vector according to the fifteenth aspect of the invention or has integrated into its genome a polynucleotide according to the fourteenth aspect of the invention.
[0043] In a seventeenth aspect of the present invention, there is provided a method for detecting (including diagnostic or non-diagnostic) CLDN18.2 protein in a sample in vitro, the method comprising the steps of: (1) contacting the sample in vitro with an antibody according to the fifth aspect of the invention; (2) detecting whether an antigen-antibody complex is formed, where the formation of the complex indicates the presence of the CLDN18.2 protein in the sample;
[0044] In an eighteenth aspect of the present invention, there is provided a detection plate comprising a substrate (support plate) and a test strip containing an antibody according to the fifth aspect of the present invention or an antibody-drug complex according to the eleventh aspect of the present invention.
[0045] In a nineteenth aspect of the present invention there is provided a kit comprising: (1) a first container containing an antibody according to the fifth aspect of the invention, and / or (2) a second container containing a secondary antibody against the antibody according to the fifth aspect of the invention; Alternatively, there is provided a kit containing a detection plate according to the eighteenth aspect of the invention.
[0046] In a twentieth aspect of the present invention, there is provided a method for producing a recombinant polypeptide, the method comprising the steps of: (a) culturing a host cell according to the fourteenth aspect of the invention under conditions suitable for expression; (b) isolating a recombinant polypeptide from the culture, which is an antibody according to the fifth aspect of the invention or a recombinant protein according to the sixth aspect of the invention.
[0047] In a twenty-first aspect of the present invention, there is provided a method of treating a CLDN18.2-associated disease, the method comprising the step of administering to a subject in need thereof an antibody described in the fifth aspect of the present invention, an antibody-drug conjugate of said antibody, or a CAR-T cell expressing said antibody, or a combination thereof.
[0048] Of course, it is understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (for example, in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be described here one by one due to space limitations. [Brief description of the drawings]
[0049] [Figure 1] FIG. 1 shows the results of ELISA binding detection of hybridoma supernatant cells. [Figure 2A] Figure 2 shows the results of flow cytometry detection. Figure 2A shows the results of chimeric antibody ch429, Figure 2B shows the results of chimeric antibody ch623, Figure 2C shows the results of chimeric antibody ch624, Figure 2D shows the results of chimeric antibody ch782, and Figure 2E shows the results of reference antibody Ref.ch175. [Figure 2B]Figure 2 shows the results of flow cytometry detection. Figure 2A shows the results of chimeric antibody ch429, Figure 2B shows the results of chimeric antibody ch623, Figure 2C shows the results of chimeric antibody ch624, Figure 2D shows the results of chimeric antibody ch782, and Figure 2E shows the results of reference antibody Ref.ch175. [Figure 2C] Figure 2 shows the results of flow cytometry detection. Figure 2A shows the results of chimeric antibody ch429, Figure 2B shows the results of chimeric antibody ch623, Figure 2C shows the results of chimeric antibody ch624, Figure 2D shows the results of chimeric antibody ch782, and Figure 2E shows the results of reference antibody Ref.ch175. [Figure 2D] Figure 2 shows the results of flow cytometry detection. Figure 2A shows the results of chimeric antibody ch429, Figure 2B shows the results of chimeric antibody ch623, Figure 2C shows the results of chimeric antibody ch624, Figure 2D shows the results of chimeric antibody ch782, and Figure 2E shows the results of reference antibody Ref.ch175. [Figure 2E] Figure 2 shows the results of flow cytometry detection. Figure 2A shows the results of chimeric antibody ch429, Figure 2B shows the results of chimeric antibody ch623, Figure 2C shows the results of chimeric antibody ch624, Figure 2D shows the results of chimeric antibody ch782, and Figure 2E shows the results of reference antibody Ref.ch175. [Figure 3A] Figure 3 shows the results of detecting the binding activity of anti-CLDN18.2 human mouse chimeric antibody to recombinant cells. Figure 3A shows the results of the binding activity of anti-CLDN18.2 human mouse chimeric antibody to HEK293-hCLDN18.1 cells, and Figure 3B shows the results of the binding activity of anti-CLDN18.2 human mouse chimeric antibody to HEK293-hCLDN18.2 cells. [Figure 3B] Figure 3 shows the results of detecting the binding activity of anti-CLDN18.2 human mouse chimeric antibody to recombinant cells. Figure 3A shows the results of the binding activity of anti-CLDN18.2 human mouse chimeric antibody to HEK293-hCLDN18.1 cells, and Figure 3B shows the results of the binding activity of anti-CLDN18.2 human mouse chimeric antibody to HEK293-hCLDN18.2 cells. [Figure 4]FIG. 4 shows the results of detecting the binding activity of anti-CLDN18.2 human-mouse chimeric antibody to NUGC4 cells. [Diagram 5] FIG. 5 shows the results of flow cytometry detection of the cell binding activity of anti-CLDN18.2 human-mouse chimeric antibody to recombinant cells. [Figure 6] FIG. 6 shows the results of ADCC activity of anti-CLDN18.2 human-mouse chimeric antibody against HEK293-hCLDN18.2 cells. [Figure 7A] FIG. 7 shows the binding activity of humanized antibodies to human CLDN18.1 & CLDN18.2, mouse CLDN18.1 & CLDN18.2, and NUGC4 cells. [Figure 7B] FIG. 7 shows the binding activity of humanized antibodies to human CLDN18.1 & CLDN18.2, mouse CLDN18.1 & CLDN18.2, and NUGC4 cells. [Figure 7C] FIG. 7 shows the binding activity of humanized antibodies to human CLDN18.1 & CLDN18.2, mouse CLDN18.1 & CLDN18.2, and NUGC4 cells. [Figure 7D] FIG. 7 shows the binding activity of humanized antibodies to human CLDN18.1 & CLDN18.2, mouse CLDN18.1 & CLDN18.2, and NUGC4 cells. [Figure 7E] FIG. 7 shows the binding activity of humanized antibodies to human CLDN18.1 & CLDN18.2, mouse CLDN18.1 & CLDN18.2, and NUGC4 cells. [Figure 8A] FIG. 8 shows the ADCC activity of humanized antibodies. [Figure 8B] FIG. 8 shows the ADCC activity of humanized antibodies. [Figure 8C] FIG. 8 shows the ADCC activity of humanized antibodies. [Figure 9] FIG. 9 shows the results of detecting the CDC activity of humanized antibodies. [Figure 10] FIG. 10 shows the results of the growth-inhibitory activity of humanized antibodies against HEK293-hCLDN18.2. [Figure 11A]Figure 11 shows a comparison of the primary binding sites of the antibody hu782 of the present invention and a reference antibody, where Figure 11A shows the primary binding site of Ref.ch175 and Figure 11B shows the primary binding site of the antibody hu782 of the present invention. [Figure 11B] Figure 11 shows a comparison of the primary binding sites of the antibody hu782 of the present invention and a reference antibody, where Figure 11A shows the primary binding site of Ref.ch175 and Figure 11B shows the primary binding site of the antibody hu782 of the present invention. [Figure 12] FIG. 12 shows the in vivo antitumor activity of the antibody of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0050] The present inventors have conducted extensive and in-depth research and have unexpectedly obtained an anti-human CLDN18.2 antibody with high affinity and high antitumor activity for the first time. Specifically, the present inventors have conducted extensive screening and have obtained a mouse-derived antibody with high affinity to multiple strains of human CLDN18.2 for the first time. In the present invention, chimeric and humanized antibodies are further produced based on the mouse-derived antibody, and the obtained humanized antibody is screened for mutations. The antibody of the present invention, especially the humanized antibody after mutation, has affinity close to that of the chimeric antibody, and has the potential to be developed into a humanized monoclonal antibody drug for targeted therapy. The antibody of the present invention can effectively bind to human CLDN18.2, inhibit the proliferation of many tumor cells, inhibit the growth of tumors in nude mice, and has excellent antitumor activity. Based on this, the present invention has been completed.
[0051] Specifically, the inventors constructed multiple forms of hCLDN18.2 DNA and alternately immunized mice with them as antigens, and then performed reinforcement immunization with a recombinant cell line expressing hCLDN18.2, and obtained mouse monoclonal antibodies mab429, mab623, mab624, and mab782 that specifically recognize hCLDN18.2 through hybridoma fusion technology.
[0052] The chimeric antibody ch782 can specifically bind to hCLDN18.2 and recognize the CLDN18.2 molecule on the cell surface of tumor cell NUGC4, and has higher affinity with CLDN18.2 than the reference antibody Ref.ch175. Ch782 has ADCC, CDC and growth inhibitory activity against hCLDN18.2 cells.
[0053] The chimeric antibody ch782 was humanized to obtain four IgG1 type humanized antibody combinations, hu782H1.1L1, hu782H1.2L1, hu782H1.1L2, and hu782H1.2L2. The four humanized antibodies specifically recognize hCLDN18.2 and have comparable affinity for ch782.
[0054] The humanized antibody heavy chain hu782H1.1 was subjected to point mutation at the S60A site to remove potential glycosylation sites, and at the same time, the expression level was increased by mutation at the V101A site to obtain the humanized antibody heavy chain hu782 H1.2-V101A. The above S60A and V101A sites are defined according to the Kabat numbering convention.
[0055] The humanized antibodies hu782 (H1.2L2 combination) and hu782-HV (H1.2-V101A L2 combination) had significantly better ADCC activity against tumor cells than the reference antibody Ref.ch175.
[0056] The humanized antibody hu782-DE was obtained by performing S239D / I332E mutations on the 239th and 332nd amino acids of the heavy chain constant region of the humanized antibody hu782. The above S239D and I332E are defined according to the EU numbering system.
[0057] The humanized antibody hu782-DE had significantly better ADCC against tumor cells NUGC4 than the reference antibody Ref.ch175, and its EC50 value was 24-fold lower than that of Ref.ch175.
[0058] The humanized antibodies hu782 and hu782-HV have CDC killing activity against hCLDN18.2 target cells. The humanized antibodies hu782 and hu782-HV have proliferation-inhibitory activity against hCLDN18.2 target cells, and the proliferation-inhibitory activity is dose-dependent and significantly better than that of the reference antibody Ref.ch175.
[0059] Epitope analysis found that the main recognition sites of humanized antibody hu782 included the E56 and G48 sites of the hCLDN18.2 molecule, while the main recognition sites of reference antibody Ref.ch175 included the A42S, N45A, E56A, and G48 sites, demonstrating that there are certain differences in the binding epitopes of the two antibodies.
[0060] In nude mouse tumor transplantation model, the three antibodies hu782, hu782-HV, and hu782-DE can all significantly inhibit tumor growth, and are better than the reference antibody Ref.ch175, and in particular, the two antibodies hu782 and hu782-DE have significantly better tumor growth inhibition effects than the reference antibody Ref.ch175. In both hu782 and hu782-DE treatment groups, the tumors in the mice completely regressed, with the tumor inhibition rates of hu782-HV, hu782, and hu782-DE being 34.68%, 62.88%, and 65.05%, respectively, and the reference antibody Ref.ch175 being 15.5%.
[0061] term To facilitate understanding of this disclosure, certain terms are first defined. As used in this application, unless expressly defined otherwise herein, all of the following terms have the following meanings. Additional definitions are set forth throughout the application.
[0062] The term "about" refers to a value or composition that is within an acceptable error range for a particular value or composition, as determined by one of ordinary skill in the art, which in part determines how the value or composition is quantified or measured. For example, as used herein, the designation "about 100" includes 99 and 101 and all values therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0063] As used herein, the terms "containing" or "comprises" may refer to open, semi-closed and closed systems. In other words, the terms also include "consisting essentially of" or "consisting of."
[0064] Sequence identity is determined by comparing two aligned sequences along a given comparison window (which may be 50%, 60%, 70%, 80%, 90%, 95% or 100% of the length of the reference nucleotide sequence or protein) and by the number of positions in which similar residues appear. Usually expressed as a percentage. Measuring sequence identity of nucleotide sequences is a method well known to those skilled in the art.
[0065] As used herein, the terms "heavy chain variable region" and "V H " can be used interchangeably. As used herein, the terms "light chain variable region" and "V L " can be used interchangeably.
[0066] As used herein, the terms "variable region" and "complementarity determining region (CDR)" can be used interchangeably.
[0067] In the present invention, the terms "antibody of the invention," "protein of the invention," or "polypeptide of the invention" are used interchangeably and all refer to an antibody that specifically binds to CLDN18.2, such as a protein or polypeptide having a heavy chain variable region (e.g., the amino acid sequence of SEQ ID NO: 1, 11, 12, or 13) and / or a light chain variable region (e.g., the amino acid sequence of SEQ ID NO: 6, 14, or 15), which may or may not contain an initial methionine.
[0068] Another preferred antibody of the present invention is an antibody that specifically binds to CLDN18.2 corresponding to 624, such as a protein or polypeptide having a heavy chain variable region (e.g., the amino acid sequence of SEQ ID NO:23) and / or a light chain variable region (e.g., the amino acid sequence of SEQ ID NO:24).
[0069] CLDN18.2 Human CLDN18 is a four-transmembrane protein with a total length of 261 amino acids, four transmembrane hydrophobic domains, and two loop structures in the extracellular space, with loop 1 consisting of transmembrane domain 1 and transmembrane domain 2 in a circular loop, and loop 2 consisting of transmembrane domain 3 and transmembrane domain 4 in a circular loop. Human CLDN18.1 and CLDN18.2 have different amino acid compositions in the N-terminus, transmembrane domain 1, and extracellular loop 1, but the other parts are completely identical, with a sequence similarity of 92%.
[0070] antibody As used herein, the term "antibody" refers to an immunoglobulin, which is a four-chain peptide structure consisting of two identical heavy chains and two identical light chains linked through disulfide bonds.
[0071] Existing antibody numbering schemes include the following: 1. The Kabat scheme (Kabat et al., 1991) is based on the location of regions of high sequence variation between sequences of the same domain type and differs in the numbering of the heavy (VH) and light (Vλ and Vκ) variable domains of antibodies. 2. The Chothia scheme (Al-Lazikani, 1997) is similar to the Kabat scheme, but with annotations around the first VH complementarity Determining Region (CDR) inserted at positions corresponding to structural loops. Similarly, the Enhanced Chothia scheme (Abhinandan and Martin, 2008) is a further structural modification of the inserted positions. 3. In contrast to these Kabat-like schemes, IMGT (Lefranc, 2003) and AHo (Honegger and Pluckthun, 2001) are both unique schemes for defining variable domains in antibodies and T cell receptors (TCRs) (Vα and Vβ), allowing easy comparison of positions of equal effect between domain types. IMGT and AHo differ in the number of annotated positions (128 and 149, respectively) and in the positions where indels are considered to occur.
[0072] The antigenicity of an immunoglobulin varies depending on the amino acid composition and sequence of the heavy chain constant region. Thus, immunoglobulins are divided into five types, or called immunoglobulin isotypes, namely IgM, IgD, IgG, IgA, and IgE, and the corresponding heavy chains are μ, δ, γ, α, and ε chains, respectively. The same Ig can be divided into different subtypes depending on the amino acid composition of its hinge region and the number and position of the heavy chain disulfide bonds, for example, IgG can be divided into IgG1, IgG2, IgG3, and IgG4. The light chain can be divided into κ or λ chains depending on the constant region. Of the five types of Ig, any Ig may have κ or λ chains. The subunit structure and three-dimensional structure of each class of immunoglobulin are well known to those skilled in the art.
[0073] The light chain of the antibody according to the present invention may further comprise a light chain constant region, said light chain constant region comprising a kappa chain, a lambda chain or a variant thereof of human or murine origin.
[0074] In the present invention, the heavy chain of the antibody according to the present invention may further comprise a heavy chain constant region, which includes IgG1, IgG2, IgG3, IgG4 or variants thereof of human or mouse origin. The sequences of about 110 amino acids near the N-terminus of the heavy and light chains of the antibody are highly different and are the variable region (Fv region), while the remaining amino acid sequences near the C-terminus are relatively stable and are the constant region. The variable region comprises three hypervariable regions (HVR) and four framework regions (FR) whose sequences are relatively conserved. The three hypervariable regions determine the specificity of the antibody and are also called complementarity determining regions (CDR). Each light chain variable region (LCVR) and heavy chain variable region (HCVR) consists of three CDR regions and four FR regions, which are arranged from the amino terminus to the carboxy terminus in the order FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The three CDR regions of the light chain are referred to as LCDR1, LCDR2 and LCDR3, and the three CDR regions of the heavy chain are referred to as HCDR1, HCDR2 and HCDR3. In Example 13 of the present invention, the Kabat and Chothia scheme is combined to divide the six CDRs of the ch782 antibody.
[0075] In the present invention, the term "mouse-derived antibody" refers to an anti-CLDN18.2 monoclonal antibody produced by the knowledge and skill of the art. During production, a test subject is injected with CLDN18.2 antigen, and then hybridomas expressing an antibody having the required sequence or functional characteristics are isolated. In one preferred embodiment of the present invention, the mouse-derived CLDN18.2 antibody or antigen-binding fragment thereof may further comprise a light chain constant region of a mouse-derived κ chain, λ chain or variant thereof, or a heavy chain constant region of a mouse-derived IgG1, IgG2, IgG3 or variant thereof.
[0076] The term "chimeric antibody" refers to an antibody that is made by fusing the variable region of a mouse-derived antibody with the constant region of a human antibody, and is capable of reducing the immune response caused by mouse-derived antibodies.
[0077] The term "humanized antibody", also called CDR-grafted antibody, refers to an antibody in which mouse CDR sequences are grafted onto the framework of a human antibody variable region, i.e., onto a framework sequence of an antibody of a different human species. Humanized antibodies can overcome the heterologous reaction induced by chimeric antibodies having a large amount of mouse protein components. Such framework sequences can be obtained from public DNA databases or published references that contain gene sequences of antibodies of the same series. To prevent a decrease in immunogenicity and therefore a decrease in activity, the activity can be maintained by making a minimum of reverse mutations or back mutations in the framework sequences of the variable regions of the human antibody.
[0078] The term "antigen-binding fragment of an antibody" (or simply "antibody fragment") refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., CLDN18.2). It has been shown that fragments of a full-length antibody can perform the antigen-binding function of an antibody. Examples of binding fragments encompassed by the term "antigen-binding fragment of an antibody" include the following: (i) a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) F(ab')2 fragment, a bivalent fragment containing two Fab fragments linked by disulfide bridges in the hinge region; (iii) an Fd fragment consisting of the VH and CH1 domains; (iv) An Fv fragment consisting of the VH and VL domains of one arm of an antibody.
[0079] Fv antibody is the minimum antibody fragment that contains the heavy chain variable region and the light chain variable region of an antibody, but lacks the constant region and has all antigen-binding sites. In general, Fv antibody further contains a polypeptide linker between the VH and VL domains and can form the structure required for antigen binding.
[0080] The term "CDR" refers to one of the six hypervariable regions in the variable domain of an antibody that primarily mediates antigen binding. One of the most commonly used definitions of the six CDRs is provided by Kabat EA et al. (1991) Sequences of proteins of immunological interest. NIH Publication 91-3242).
[0081] The term "epitope" or "antigenic determinant" refers to a site on an antigen to which an immunoglobulin or antibody specifically binds (e.g., a particular site on a CLDN18.2 molecule). An epitope usually includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive or non-consecutive amino acids in a unique conformation.
[0082] The terms "specific binding," "selective binding," "selectively binds," and "specifically binds" refer to the binding of an antibody to a predetermined epitope on an antigen. Typically, an antibody binds to an antigen at a concentration of about 10 -7 Less than M, for example, about 10 -8 M, 10 -9 M or 10 -10 It binds with an affinity (KD) less than or equal to M.
[0083] The term "competitively binds" refers to an antibody that recognizes the same epitope (also called antigenic determinant) or a part of the same epitope in the extracellular domain of CLDN18.2 as the monoclonal antibody of the present invention and binds to the antigen. An antibody that binds to the same epitope as the monoclonal antibody of the present invention is an antibody that recognizes and binds to the amino acid sequence of CLDN18.2 recognized by the monoclonal antibody of the present invention.
[0084] The term "KD" or "Kd" refers to the dissociation equilibrium constant of a particular antibody-antigen interaction. Typically, the antibodies of the present invention have an affinity for about 10 -7 Less than M, for example, about 10 -8 M, 10 -9 M or 10 -10It binds to CLDN18.2 with a dissociation equilibrium constant (KD) less than or equal to M.
[0085] As used herein, the term "antigenic determinant" refers to a discrete spatial site on an antigen that is recognized by an antibody or antigen-binding fragment of the present invention. The present invention includes not only complete antibodies, but also immunologically active antibody fragments or fusion proteins consisting of antibodies and other sequences, and therefore further includes fragments, derivatives and analogs of said antibodies.
[0086] In the present invention, antibodies include murine antibodies, chimeric antibodies, humanized antibodies or fully human antibodies produced by techniques familiar to those skilled in the art. Recombinant antibodies, such as chimeric monoclonal antibodies and humanized monoclonal antibodies, contain human and non-human portions and can be produced by recombinant DNA techniques familiar to those skilled in the art.
[0087] As used herein, the term "monoclonal antibody" refers to an antibody secreted from a clone derived from a single cell. Monoclonal antibodies are highly specific and directed against a single epitope. The cell may be a clonal cell line, eukaryotic, prokaryotic or phage. In the present invention, antibodies may be monospecific, bispecific, trispecific or of greater multispecificity.
[0088] In the present invention, the antibody of the present invention further includes its conservative variants, and refers to a polypeptide in which, compared with the amino acid sequence of the antibody of the present invention, 10 or less, preferably 8 or less, more preferably 5 or less, and most preferably 3 or less amino acids are substituted with amino acids having similar or close properties. These conservative variant polypeptides are preferably generated by making amino acid substitutions based on the following table. [Table 1]
[0089] Anti-CLDN18.2 humanized antibody The present invention provides an anti-CLDN18.2 humanized antibody (hereinafter, abbreviated as CLDN18.2 antibody). Specifically, the present invention provides a humanized antibody with high specificity and high affinity for CLDN18.2, which comprises a heavy chain and a light chain, the heavy chain containing the amino acid sequence of a heavy chain variable region (VH), and the light chain containing the amino acid sequence of a light chain variable region (VL).
[0090] In 1986, Jones et al. were the first to graft the heavy chain CDR of a mouse monoclonal antibody onto the heavy chain framework region of a human antibody, and then assembled it into a complete antibody with the light chain of a mouse monoclonal antibody to maintain affinity similar to that of the original mouse monoclonal antibody, providing a new idea for the development of antibody humanization technology. In 1989, Queen et al. succeeded in constructing an anti-CD25 humanized antibody by the CDR grafting method, in which humanization was performed using the human antibody framework region, and affinity was maintained by leaving the amino acids of the mouse-derived antibody at some sites in the framework region. In 1992, Presta et al. reported a method in which the consensus sequence of a subgroup of human antibodies was used as a template to successfully construct a humanized antibody by CDR grafting. In 1994, Pedersen et al. reported humanizing an antibody by the resurfacing method. In 1994, Hsiao et al. reported a humanization method in which CDRs were grafted onto framework regions of human antibody germline sequences. In 1994, Jespers et al. succeeded in constructing a humanization method using a phage library (shuffling library).
[0091] In antibody humanization, there are usually two types of human framework region selection: one is a known mature antibody, and the other is a human germline sequence. The framework region of a known mature antibody usually contains somatic mutation sites, which may lead to potential immunogenicity. Compared with a mature antibody, the framework region of a human germline is theoretically less immunogenic, and the structure is more flexible, more adaptable, and more likely to accept different CDR regions. Human antibody germline genes have a certain tendency to be used frequently in the human body, and antibodies humanized with framework regions of germline sequences that are used frequently have the advantages of low immunogenicity, high expression, and stable structure.
[0092] In one preferred embodiment of the present invention, when humanizing, the framework region of the most optimized sequence is selected through screening of both similarity and frequency of use in humans, instead of the germline sequence with the highest similarity to mouse-derived antibodies, and CDR grafting is performed in the framework region of the germline human antibody, and the humanized antibody constructed in this way has a more stable structure, a higher expression level, a lower immunogenicity, and a higher drug-likeness.
[0093] In another preferred embodiment, the heavy chain constant region and / or the light chain constant region may be a humanized heavy chain constant region or a human light chain constant region, more preferably a human IgG1, IgG2, or the like heavy chain constant region, or a human κ, λ light chain constant region.
[0094] In another preferred embodiment, the sequence having at least one amino acid addition, deletion, modification and / or substitution is preferably an amino acid sequence having at least 80% homology, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% homology. The antibodies of the present invention may be double-chain or single-chain antibodies, and preferably are fully humanized antibodies.
[0095] The antibody derivatives of the present invention may be single chain antibodies and / or antibody fragments, such as Fab, Fab', (Fab')2, or other antibody derivatives known in the art, as well as any one or more of IgA, IgD, IgE, IgG and IgM antibodies or other subtypes of antibodies. The antibodies of the present invention may be humanized, CDR-grafted and / or modified antibodies targeting CLDN18.2.
[0096] In the above-mentioned content of the present invention, the number of added, deleted, modified and / or substituted amino acids is preferably 40% or less of the total number of amino acids in the original amino acid sequence, more preferably 35% or less, more preferably 1 to 33%, more preferably 5 to 30%, more preferably 10 to 25%, and more preferably 15 to 20%.
[0097] Antibody production Any method suitable for generating monoclonal antibodies can be used to generate the CLDN18.2 antibodies of the present invention. For example, animals can be immunized with a conjugated or naturally occurring CLDN18.2 protein or a fragment thereof. Any suitable immunization method, including adjuvants, immunostimulants, and booster immunizations, can be used, and one or more methods can be used.
[0098] Any suitable form of CLDN18.2 can be used as an immunogen (antigen) to generate non-human antibodies specific to CLDN18.2 and screen the antibodies for biological activity. The immunogen can be used alone or in combination with one or more immunogenic adjuvants known in the art. The immunogen can be purified from natural sources or produced in genetically modified cells. DNA encoding the immunogen can be of genomic or non-genomic origin (e.g., cDNA). DNA encoding the immunogen can be expressed in a suitable genetic vector, including but not limited to adenovirus vectors, baculovirus vectors, plasmids and non-viral vectors.
[0099] The humanized antibody may be selected from any type of immunoglobulin, including IgM, IgD, IgG, IgA and IgE. Similarly, any light chain may be used in the compounds and methods herein. Specifically, kappa chains, lambda chains or variants thereof are useful in the compounds and methods of the present invention.
[0100] The sequence of a DNA molecule encoding an antibody or fragment thereof of the present invention can be obtained by conventional techniques, such as PCR amplification or genomic library screening, and the coding sequences for the light and heavy chains may be fused together to form a single chain antibody.
[0101] Once the relevant sequence is obtained, it can be obtained in large quantities by recombinant techniques, typically by cloning the sequence into a vector, introducing it into a cell, and isolating the relevant sequence from the host cells which have been grown in the usual manner. Alternatively, the relevant sequences may be synthesized by artificial synthesis, especially if the fragments are short in length. Typically, many small fragments are synthesized and then joined together to obtain a longer fragment of the sequence. The DNA sequence may then be introduced into a variety of known DNA molecules (or vectors, etc.) or cells known in the art.
[0102] The term "nucleic acid molecule" refers to DNA molecules and RNA molecules. Nucleic acid molecules can be single-stranded or double-stranded, but are preferably double-stranded DNA. A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
[0103] The term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. In one embodiment, the vector is a "plasmid", which refers to a circular double stranded DNA loop into which another DNA segment can be ligated. The present invention further relates to vectors containing the appropriate DNA sequences as described above and appropriate promoter or control sequences, which can be used to transform an appropriate host cell so as to express the protein.
[0104] The term "host cell" is a cell into which an expression vector has been introduced. A host cell can be a prokaryotic cell, such as a bacterial cell, or a lower eukaryotic cell, such as a yeast cell, or a higher eukaryotic cell, such as a plant or animal cell (e.g., a mammalian cell).
[0105] The process of transforming a host cell by DNA recombination according to the present invention may be carried out by techniques well known in the art. The resulting transformant can be cultured in a conventional manner to express the polypeptide encoded by the gene of the present invention. Depending on the host cell used, it is cultured in a conventional medium under appropriate conditions.
[0106] Typically, the host cells obtained by transformation are cultured under conditions suitable for the expression of the antibody of the present invention, and the antibody of the present invention is obtained by purifying the antibody by a conventional globulin purification process, such as protein A-Sepharose, hydroxyapatite chromatography, gel electrophoresis, dialysis, ion exchange chromatography, hydrophobic chromatography, molecular sieve chromatography, affinity chromatography, or other conventional separation and purification means familiar to those skilled in the art.
[0107] The monoclonal antibodies obtained can be identified by conventional means, for example, the binding specificity of the monoclonal antibodies can be determined by immunoprecipitation or by in vitro binding assays such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA).
[0108] Antibody preparations Antibodies have different stabilities in different formulation buffers, which manifest as changes in charge heterogeneity, antibody molecule decomposition, and multimerization. These changes in mass properties are related to the physical and chemical properties of the antibody itself, so in the process of antibody drug development, it is necessary to screen suitable formulation buffers according to the physical and chemical properties of different antibodies. Currently, commonly used buffer systems for antibody production include phosphate buffer, citrate buffer, histidine buffer, etc. At the same time, different concentrations of salt ions or excipients such as sorbitol, trehalose, and sucrose, as well as an appropriate amount of surfactants such as twine, may be added according to the properties of the antibody to maintain the stability of the antibody.
[0109] Drug Composition Furthermore, the present invention provides a composition. In a preferred embodiment, the composition is a pharmaceutical composition, which contains the above-mentioned antibody or its active fragment, or its fusion protein, or its ADC, or corresponding CAR-T cells, and a pharma- ceutically acceptable carrier. Usually, these substances are formulated in a non-toxic, inert, pharma- ceutically acceptable aqueous carrier, and the pH value is usually about 5 to 8, preferably about 6 to 8, depending on the nature of the formulated substance and the disease to be treated. The formulated pharmaceutical composition can be administered by a conventional route, including, but not limited to, intratumoral, intraperitoneal, intravenous, or local administration.
[0110] The antibodies of the present invention may be expressed intracellularly via the nucleotide sequence and used in cell therapy, for example, the antibodies may be used in chimeric antigen receptor T cell immunotherapy (CAR-T). The pharmaceutical composition of the present invention can be used to directly bind to the CLDN18.2 protein molecule, and is therefore useful for the prevention and treatment of CLDN18.2-related diseases, and may be used in combination with other therapeutic agents.
[0111] The pharmaceutical composition of the present invention comprises a safe and effective amount (e.g., 0.001-99 wt%, preferably 0.01-90 wt%, more preferably 0.1-80 wt%) of the above-mentioned monoclonal antibody of the present invention (or its complex) and a pharma- ceutically acceptable carrier or excipient. Such vehicles include, but are not limited to, saline, buffer, glucose, water, glycerin, ethanol, and combinations thereof. The pharmaceutical formulation corresponds to the administration form. The pharmaceutical composition of the present invention may be an injection, which can be prepared by a conventional method, for example, in physiological saline or an aqueous solution containing glucose and other auxiliary agents. In the case of an injection or solution, the pharmaceutical composition is prepared under aseptic conditions. The dosage of the active ingredient is a therapeutically effective amount, for example, about 1 μg / kg body weight to about 5 mg / kg body weight daily. The polypeptide of the present invention can also be used in combination with other therapeutic agents.
[0112] When using the pharmaceutical composition, a safe and effective amount of the pharmaceutical composition is administered to a mammal, and the safe and effective amount is usually at least about 10 μg / kg body weight, and in many cases is less than about 50 mg / kg body weight, and the dosage is preferably about 10 μg / kg body weight to about 20 mg / kg body weight.Of course, the specific dosage should further consider factors such as the mode of administration and the health condition of the patient, and all are within the skill of a skilled doctor.
[0113] Detection Applications and Kits The antibodies of the present invention are useful in the detection, for example, of analytes, and can provide diagnostic information. In the present invention, the specimen (sample) used includes cells, tissue specimens and biopsy specimens. The term "biopsy" as used in the present invention includes all types of biopsy known to those skilled in the art. Thus, biopsy as used in the present invention includes tissue specimens prepared, for example, by endoscopic methods or by puncture or needle stick of an organ.
[0114] Samples for use in the present invention include fixed or preserved cell or tissue samples. The present invention also provides a kit containing the antibody of the present invention (or a fragment thereof), and in a preferred embodiment of the present invention, the kit further comprises a container, an instruction manual, a buffer solution, etc. In a preferred embodiment, the antibody of the present invention may be immobilized on a detection plate.
[0115] The main advantages of the present invention are: 1. The antibody of the present invention has a typical structure with good tryptophan and tyrosine embedding, the template structure of the screened human VH and VL framework regions is stable, and it has good compatibility with the CDR regions of mouse monoclonal antibodies, with favorable matching of the light and heavy chain variable regions, high affinity, and stable structure. 2. Compared with chimeric antibodies, the humanized antibodies of the present invention have superior biological activity, specificity, and have lower immunogenicity and higher expression levels while maintaining affinity comparable to CLDN18.2. 3. The humanized antibody of the present invention has significant in vitro biological activity, and can effectively inhibit the proliferation of tumor cells cultured in vitro, with activity better than that of the control antibody. 4. The humanized antibody of the present invention has significant biological activity in vivo, and has excellent inhibitory activity against tumor cells such as human gastric cancer cells, which is better than that of the control antibody.
[0116] The present invention will be further described below with reference to specific examples. It is understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. Experimental methods for which no specific conditions are given in the following examples are generally performed according to standard conditions, such as those described in Sambrook et al., "Molecular Cloning: A Laboratory Manual" (New York, Cold Spring Harbor Laboratory Press, 1989), or according to the manufacturer's recommended conditions. Unless otherwise stated, percentages and parts are by weight. Unless otherwise stated, all materials or reagents used in the examples of the present invention are commercially available.
[0117] Materials and Methods 1. Reference antibody The reference antibody used in the present invention is derived from the antibody sequence of the 175D10 clone in patent US8168427. The 175D10 antibody is also called IMAB362. The sequence of the variable region of the 175D10 antibody was synthesized by total gene synthesis and constructed into a eukaryotic expression vector containing the IgG1 chimeric antibody constant region, expressed and purified. In the present invention, the prepared reference antibody is abbreviated as Ref.ch175.
[0118] The reference antibody Ref.ch175 (or IMAB362) specifically recognizes the extracellular loop 1 portion of CLDN18.2, does not bind to CLDN18.1, and kills tumor cells mainly through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
[0119] Example 1: Construction of a cell line stably expressing CLDN18.1 or CLDN18.2 In this example, cell lines stably expressing human CLDN18.1, human CLDN18.2, mouse CLDN18.1, and mouse CLDN18.2 were constructed as follows.
[0120] Full-length gene fragments encoding human CLDN18.1 (NP_057453.1) and human CLDN18.2 (NP_001002026.1) were synthesized, and the full-length fragments were cleaved with Xhol+BamHI enzymes and cloned into pEGFP-N2 eukaryotic expression vectors (purchased from Clontech), named pEGFP-N2-hCLDN18.1 and pEGFP-N2-hCLDN18.2, respectively.
[0121] HEK293 cells (purchased from the Cell Archives of the Chinese Academy of Sciences, GNHu43) were cultured at 4 × 10 5The cells were seeded at 1000 cells / well into a 6-well plate, and the next day, pEGFP-N2-hCLDN18.1 and pEGFP-N2-hCLDN18.2 were transfected into HEK293 cells using the lipofection reagent LipoMax. 24 h after transfection, the cells were subcultured at a ratio of 1:10. When the cells attached to the wall, G418 (purchased from Gibco) was added to a final concentration of 300 μg / ml to perform pressure screening. HEK293 cells stably expressing human CLDN18.1 and human CLDN18.2 membrane proteins were obtained by subcloning, and these were named HEK293-hCLDN18.1 and HEK293-hCLDN18.2, respectively.
[0122] The full-length gene fragments encoding mouse CLDN18.1 (NP_062789.1) and mouse CLDN18.2 (NP_001181850.1) were synthesized, cut by KpnI+XbaI enzymes, and cloned into pcDNA3.1-P2A-EGFP eukaryotic expression vector (purchased from Nanjing genscript Co., Ltd.), named pcDNA3.1-mCLDN18.1 and pcDNA3.1-mCLDN18.1, respectively. They were transfected into HEK293 cells by the same method as above to obtain cells stably expressing mouse CLDN18.1 and CLDN18.2 membrane proteins, named HEK293-mCLDN18.1 and HEK293-mCLDN18.2, respectively.
[0123] >NP_057453.1 Claudin-18 isoform 1 precursor [Homo sapiens] SEQ ID NO: 25 MSTTTCQVVAFLLSILGLAGCIAATGMDMWSTQDLYDNPVTSVFQYEGLWRSCVRQSSGFTECRPYFTILGLPAMLQAVRALMIVGIVLGAIGLLVSIFALKCIRIGSMEDSAKANMTLTSGIMFIVSGL CAIAGVSVFANMLVTNFWMSTANMYTGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGVMMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFKASTGFGSNTKNKKIYDGGARTEDEVQSYPSKHDYV
[0124] >NP_001002026.1 Claudin-18 isoform 2 [Homo sapiens] SEQ ID NO: 26 MAVTACQGLGFVVSLIGIAGIIAATCMDQWSTQDLYNNPVTAVFNYQGLWRSCVRESSGFTECRGYFTLLGLPAMLQAVRALMIVGIVLGAIGLLVSIFALKCIRIGSMEDSAKANMTLTSGIMFIVSGL CAIAGVSVFANMLVTNFWMSTANMYTGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGVMMCIACRGLAPEETNYKAVSYHASGHSVAYKPGGFKASTGFGSNTKNKKIYDGGARTEDEVQSYPSKHDYV
[0125] >NP_062789.1 Claudin-18 isoform A1.1 precursor [Mus musculus] SEQ ID NO: 27 MATTTCQVVGLLLSLLGLAGCIAATGMDMWSTQDLYDNPVTAVFQYEGLWRSCVQQSSGFTECRPYFTILGLPAMLQAVRALMIVGIVLGVIGILVSIFALKCIRIGSMDDSAKAKMTLTSGILFIISGICA IIGVSVFANMLVTNFWMSTANMYSGMGGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGVMMCIACRGLTPDDSNFKAVSYHASGQNVAYRPGGFKASTGFGSNTRNKKIYDGGARTEDDEQSHPTKYDYV
[0126] >NP_001181850.1 Claudin-18 isoform A2.1 [Mus musculus] SEQ ID NO: 28 MSVTACQGLGFVVSLIGFAGIIAATCMDQWSTQDLYNNPVTAVFNYQGLWRSCVRESSGFTECRGYFTLLGLPAMLQAVRALMIVGIVLGVIGILVSIFALKCIRIGSMDDSAKAKMTLTSGILFIISGICA IIGVSVFANMLVTNFWMSTANMYSGMGGMGGMVQTVQTRYTFGAALFVGWVAGGLTLIGGVMMCIACRGLTPDDSNFKAVSYHASGQNVAYRPGGFKASTGFGSNTRNKKIYDGGARTEDDEQSHPTKYDYV
[0127] Example 2: Preparation of immunogen Since the amino acid sequence of human CLDN18.2 extracellular loop 1 (CLDN18.2 ECL1) is completely identical to that of mouse CLDN18.2 ECL1, it is difficult to obtain an antibody that binds to CLDN18.2 ECL1. At the same time, considering that the conformation of CLDN18.2 molecules on the surface of tumor cells may be different from that on the surface of normal tissue cells, in this embodiment, multiple forms of DNA plasmids were designed as antigens to break through immune resistance and obtain an antibody that recognizes tumor cells with high affinity.
[0128] The nucleotides encoding the full-length amino acids of human CLDN18.2 ECL1 and CLDN18.2 were linked in tandem with the P2 epitope TT830-844 and the P30 epitope TT947-967 of tetanospasmin, respectively, and cloned into the eukaryotic expression vector PTT5 (purchased from Invitrogen), and named PTT5-TT-hCLDN18.2 and PTT5-TT-hCLDN18.2-ECL1, respectively. In the present invention, CLDN18.2 ECL1 was fused to the C-terminus of human IgG1 Fc and named hFc-CLDN18.2-ECL1.
[0129] TT-hCLDN18.2 Nucleotide sequence SEQ ID NO:29 CAGTACATCAAGGCCAACAGCAAGTTCATCGGCATCACCGAGCTGAAGAAGCTGGGTGGTTCCAACGACATATTCAACAACTTCACCGTGAGCTTCTGGCTGCGCGTGCCGAAGGTGAGCGCCAGCCACCTGGAGCAGTACGGTGGCGGTAGCGGAATGGCCGTGACTGCCTGTCAGGGCTTGGGGTTCGTGGTTTCACTGATTGGGATTGCGGGCATCATTGCTGCCACCTGCATGGACCAGTGGAGCACCCAAGACTTGTACAACAACCCCGTAACAGCTGTTTTCAACTACCAGGGGCTGTGGCGCTCCTGTGTCCGAGAGAGCTCTGGCTTCACCGAGTGCCGGGGCTACTTCACCCTGCTGGGGCTGCCAGCCATGCTGCAGGCAGTGCGAGCCCTGATGATCGTAGGCATCGTCCTGGGTGCCATTGGCCTCCTGGTATCCATCTTTGCCCTGAAATGCATCCGCATTGGCAGCATGGAGGACTCTGCCAAAGCCAACATGACACTGACCTCCGGGATCATGTTCATTGTCTCAGGTCTTTGTGCAATTGCTGGAGTGTCTGTGTTTGCCAACATGCTGGTGACTAACTTCTGGATGTCCACAGCTAACATGTACACCGGCATGGGTGGGATGGTGCAGACTGTTCAGACCAGGTACACATTTGGTGCGGCTCTGTTCGTGGGCTGGGTCGCTGGAGGCCTCACACTAATTGGGGGTGTGATGATGTGCATCGCCTGCCGGGGCCTGGCACCAGAAGAAACCAACTACAAAGCCGTTTCTTATCATGCCTCAGGCCACAGTGTTGCCTACAAGCCTGGAGGCTTCAAGGCCAGCACTGGCTTTGGGTCCAACACCAAAAACAAGAAGATATACGATGGAGGTGCCCGCACAGAGGACGAGGTACAATCTTATCCTTCCAAGCACGACTATGTGTAA
[0130] TT-hCLDN18.2-ECL1 nucleotide sequence: SEQ ID NO:30 CAGTACATCAAGGCCAACAGCAAGTTCATCGGCATCACCGAGCTGAAGAAGCTGGGTGGTTCCAACGACATATTCAACAACTTCACCGTGAGCTTCTGGCTGCGCGTGCCGAAGGTGAGCGCCAGCCACCTGGAGCAGTACGGTGGCGGTAGCGGACGCATGG ACCAGTGGAGCACCCAAGACTTGTACAACAAACCCCGTAACAGCTGTTTTCAACTACCAGGGGCTGTGGCGCTCCTGTGTCCGAGAGAGCTCTGGCTTCACCGAGTGCGGGGCTACTTCACCCTGCTGGGGCTGCCAGCCATGCTGCAGGCAGTGCGAGCCTAA
[0131] hFc-CLDN18.2-ECL1 Nucleotide sequence: SEQ ID NO:31 GACAAGACCCACACATGCCCACCTTGTCCAGCTCCAGAGCTGCTGGGAGGACCAAGCGTGTTCCTGTTTCCACCCAAGCCCAAGGATACACTGATGATCTCTAGGACCCCCGAGGTGACATGCGTGGTGGTGGACGTGTCCCACGAGGACCCCGAGGTGAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCTAAGACCAAGCCCAGGGAGGAGCAGTACAACAGCACCTATCGGGTGGTGTCTGTGCTGACAGTGCTGCATCAGGATTGGCTGAACGGCAAGGAGTATAAGTGCAAGGTGAGCAATAAGGCCCTGCCTGCTCCAATCGAGAAGACCATCTCTAAGGCCAAGGGCCAGCCCAGAGAGCCTCAGGTGTACACACTGCCTCCATCCCGCGAGGAGATGACCAAGAACCAGGTGAGCCTGACATGTCTGGTGAAGGGCTTCTATCCTTCTGACATCGCTGTGGAGTGGGAGTCCAATGGCCAGCCAGAGAACAATTACAAGACCACACCCCCTGTGCTGGACAGCGATGGCTCTTTCTTTCTGTATTCCAAGCTGACCGTGGATAAGAGCAGGTGGCAGCAGGGCAACGTGTTTTCCTGTAGCGTGATGCACGAGGCCCTGCACAATCATTACACACAGAAGTCTCTGTCCCTGAGCCCTGGCAAGGGATCCGGAGGAGGCTCTGGAGGCTCCGACCAGTGGAGCACCCAGGATCTGTACAACAATCCCGTGACAGCCGTGTTCAACTATCAGGGCCTGTGGAGGTCTTGCGTGCGGGAGTCCAGCGGCTTCACCGAGTGTAGAGGCTACTTTACACTGCTGGGACTGCCTGCTATGCTGCAGGCTGTGCGCTGA
[0132] Example 3: Production of anti-human CLDN18.2 hybridoma cell line Balb / c mice for the experiment were purchased from Shanghai SIPPR-BK Laboratory. All immunized mice were 4-6 weeks old, female, standardized disease-free, healthy purebred mice. CLDN18.2 is a four-transmembrane protein, and to obtain specific antibodies that recognize tumor cells with high affinity, mice were immunized with multiple plasmids and then rush immunized with cells stably expressing human CLDN18.2 membrane protein as follows.
[0133] Day 1 and Day 14: 50 μg of eukaryotic expression vector plasmid pEGFP-N2-hCLDN18.2 encoding the full-length human CLDN18.2 gene was injected into the quadriceps of mice (im) with the adjuvant In vivo-Jet PEI-Man in vivo transfection reagent (purchased from Polyplus, 203-10G). On day 28, 50 μg of eukaryotic expression plasmid hFc-CLDN18.2-ECL1 DNA was injected into the mouse quadriceps (im), on day 42, 50 μg of eukaryotic expression vector plasmid PTT5-TT-hCLDN18.2 was injected into the mouse quadriceps (im), on day 56, 50 μg of eukaryotic expression vector plasmid PTT5-TT-CLDN18.2 ECL1 was injected into the mouse quadriceps (im), and on day 70, 50 μg of eukaryotic expression vector plasmid PTT5-TT-hCLDN18.2 and 50 μg of eukaryotic expression vector plasmid PTT5-TT-CLDN18.2 ECL1 were injected into the mouse quadriceps (im).
[0134] After 14 days, the mice were bled from the tail vein and serum antibody titers were measured by cell-based ELISA. 7 The two mice with the highest antibody titers were boosted with 10000 HEK293-hCLDN18.2 cells / mouse via intraperitoneal injection. On the day of fusion, the mice were bled and their spleens were removed, and single-cell suspensions were prepared and electrofusion was performed with SP20 cells to obtain hybridomas, which were then plated. [Table 2]
[0135] Example 4: Screening of hybridoma cells that specifically bind to human CLDN18.2 but not to human CLDN18.1 In this example, hybridomas were screened by cell-based ELISA to obtain hybridoma cells that specifically bind to human CLDN18.2 but not to human CLDN18.1. The method is as follows:
[0136] HEK293-hCLDN18.1 and HEK293-hCLDN18.2 cells were digested with trypsin and then diluted with 3 × 10 5 The cells were seeded at a cell density of 100 / mL in 200 μL / well onto a 96-well plate coated with polylysine (P4707, Sigma) and cultured overnight. When the cells reached 90% or more of confluence, the supernatant was removed and the cells were fixed with 10% neutral formalin solution at room temperature for 15 min. After washing three times with PBS, the cells were blocked with 5% skim milk at 4°C overnight. To detect hybridomas, the supernatants from the same wells were added to plates coated with HEK293-hCLDN18.1 cells and HEK293-hCLDN18.2 cells at 80 μl / well, incubated at 37°C for 1 h, washed three times with PBST, and then added 100 μl / well of sheep anti-mouse IgG(H+L)-HRP diluted at 1:5000, incubated at 37°C for 45 min, incubated for 30 min, added 50 μl / well of 2M H2SO4 to stop the color development, and read the OD450 using a microplate reader.
[0137] After screening more than 10,000 clones, several hCLDN18.2-specific antibody strains were obtained, and the optimal four strains are shown in the table below. [Table 3]
[0138] Example 5: Detection of subtypes of mouse monoclonal antibodies Subtype detection was performed for the clone strains that specifically bound to CLDN18.2 using a subtype detection kit (SBA Clonotyping System-HRP kit, purchased from southernbiotech, 5300-05).
[0139] The detection results are as follows: [Table 4]
[0140] Example 6: Cloning and identification of anti-human CLDN18.2 mouse-derived monoclonal antibody variable region coding sequences Since the mouse monoclonal antibodies obtained by screening contained IgM subtype antibodies, we obtained the sequences of the variable regions of the mouse monoclonal antibodies by RACE-PCR and constructed chimeric antibodies to further evaluate their activity.
[0141] Total mRNA from the hybridoma obtained in Example 4 was extracted using the RNA extraction kit TakaRa MiniBEST Universal RNA Extration Kit (Takara, 9767), and the sequence of the variable region of the mouse-derived antibody was obtained by PCR using the SMARTer RACE 5' / 3' Kit (Clontech, 634858). The results are as follows.
[0142] Amino acid sequence of the 624 antibody heavy chain variable region (SEQ ID NO:23): QVQLQQPGAELVRPGASVKLSCKASGYSFTSYWMNWVKQRPGQGLEWIGMIHPSDSETRLNQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCARTSYGNSFAYWGQGTLVTVSA
[0143] Amino acid sequence of the 624 antibody light chain variable region (SEQ ID NO:24): DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK
[0144] Nucleotide sequence of the 782 antibody heavy chain variable region (SEQ ID NO:2): GATGTGCAGCTTCAGGAGTCAGGACCTGACCTGGTGAAACCTTCTCAGTCACTTTCACTCACCTGCACTGTCACTGGCTACTCCATCACCAGTGGTTATAGCTGGCACTGGATCCGGCAGTTTCCAGGAAACAAACTGGAATGGATGGGCTACATACACTACAGTGATAACACGAAC TACAGCCCATCTCTCAAAGGTCGAATCTCTATCACTCGAGACACATCCAAGAACCAGTTCTTCCTGCAGTTGAATTCTGTGACTACTGAGGACACAGCCACATATTACTGTGCAAGGATCTACTATGGTAACTCGTTGTTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA
[0145] Amino acid sequence of the 782 antibody heavy chain variable region (SEQ ID NO:1): DVQLQESGPDLVKPSQSLSLTCTVTGYSITSGYSWHWIRQFPGNKLEWMGYIHYSDNTNYSPSLKSRISITRDTSKNQFFLQLNSVTTEDTATYYCARIYYGNSFVYWGQGTLVTVSA
[0146] Nucleotide sequence of the 782 antibody light chain variable region (SEQ ID NO:7): GACATTGTGATGACACAGTCTCCATCCTCCCTGACTGTGACAGCAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCTGTTAAACAGTGGAAATCAAAAGAACTACTTGACCTGGTACCAGCAGAAACCAGGACAGCCTCCTAAACTGTTGATCTACTGGG CATCCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGGATCTGGAACAGATTTCACTCTCACCATCAACAGTGTGCAGGCTGAAGACCTGGCAGTTTATTACTGTCAGAATGATTATTTTTATCCGTACACGTTCGGGGGGGGGACCAAGCTGGAAATAAAA
[0147] Amino acid sequence of the 782 antibody light chain variable region (SEQ ID NO:6): DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTINSVQAEDLAVYYCQNDYFYPYTFGGGTKLEIK
[0148] Example 7: Construction and expression of anti-CLDN18.2 human-mouse chimeric antibody Primers were designed in accordance with the principles of primer design for homologous recombination, and gene fragments of the mouse-derived antibody heavy and light chain variable regions obtained in Example 6 were amplified. These were then linked to the sequences of human heavy and light chain constant regions, respectively, and constructed into the expression vector PTT5 (purchased from Invitrogen). Plasmid extraction was performed with a commercial plasmid maxi kit and transfected into 293FV suspension cells by PEI transfection method, and 7 days after transfection, the supernatant was collected and the chimeric antibody was obtained by protein A affinity chromatography.
[0149] Example 8: Specificity analysis of anti-CLDN18.2 human-mouse chimeric antibodies HEK293 cells stably transfected with human CLDN18.2 and HEK293 cells stably transfected with human CLDN18.1 were digested with trypsin and then cultured at 5 × 10 5 The cells were placed in 100 μl of hybridoma supernatant at 100 μl per 100 cells, incubated on ice for 1 hour, washed twice with FACS buffer, and then added with sheep anti-mouse IgG-PE secondary antibody diluted at 1:400. The cells were incubated on ice for 45 min, washed twice with FACS buffer, and then added with 300 μl of loading buffer. The cells were transferred to a BD flow cytometry tube and analyzed by BD FACS calibur. The mean fluorescence intensity (MFI) was analyzed by Flowjo software.
[0150] The results are shown in FIG. 2 and the table below. [Table 5]
[0151] The results showed that ch429, ch623, ch624, and ch782 specifically bind to human CLDN18.2 but not to human CLDN18.1. Among them, the MFI of the chimeric antibody ch782 is higher than that of the reference antibody Ref.ch175.
[0152] Example 9: Detection of binding activity of anti-CLDN18.2 human-mouse chimeric antibody to recombinant cells HEK293-hCLDN18.1 and HEK293-hCLDN18.2 cells were digested with trypsin, seeded at a certain cell density onto polylysine (P4707, Sigma)-coated 96-well plates, and cultured overnight. When the cells reached 90% or more confluence, the supernatant was removed and fixed with 10% formalin solution at room temperature for 15 min. After washing once with PBS, the cells were blocked with 5% nonfat milk at 4°C overnight and prepared for use. Candidate chimeric antibodies and reference antibody Ref.ch175 were diluted in a gradient of 10, starting from 1μg / ml, and 100μl / well was added to the cell-coated 96-well plate, incubated at 37℃ for 1 hour, washed 3 times with PBST, added mouse anti-human IgG Fc-HRP diluted 1:2000, incubated at 37℃ for 1 hour, washed 3 times with PBST, developed with TMB coloring solution for 15 minutes, and stopped with 2M H2SO4. OD450-OD630 values were read, and graphs were made by fitting with GraphPad Prism 8 software to calculate EC50. The results are shown in Figure 3. ch429, ch623, ch624, ch782 and reference antibody Ref.ch175 did not bind to HEK293-hCLDN18.1 cells, but specifically bound to HEK293-HCLDN18.2 cells, with ch429 and ch782 having 257.5% and 179.9% of the relative binding activity of reference antibody Ref.ch175, respectively. The results are shown in the table below. [Table 6]
[0153] Example 10: Detection of binding activity of anti-CLDN18.2 human mouse chimeric antibody to NUGC4 cells NUGC4 cells (purchased from Nanjing Kebai Biological Co., Ltd.) were spread on a 96-well plate in the same manner as in Example 9, and the candidate chimeric antibody and reference antibody Ref.ch175 were diluted from 100 μg / ml to a gradient of 10 in 3-fold dilutions, and 100 μl / well were placed in the cell-coated 96-well plate, incubated at 37 ° C for 1 hour, washed the plate three times with PBST, added mouse anti-human IgG Fc-HRP diluted 1: 2000, incubated at 37 ° C for 1 hour, washed the plate three times with PBST, colored with TMB coloring solution for 15 minutes, and stopped with 2M H2SO4. The OD450-OD630 value was read, and a graph was created by fitting with GraphPad Prism 8 software to calculate the EC50.
[0154] The results are shown in FIG. 4 and the table below. [Table 7]
[0155] The EC50 values of the chimeric antibodies ch782 and ch429 were 0.57μg / ml and 5.25μg / ml, respectively, and ch782 had a higher reading (OD450=2.3) than ch429 (OD450=1.2) at the higher concentration. No EC50 values could be calculated for ch623, ch624, or the reference antibody Ref.ch175.
[0156] This demonstrated that the ch782 antibody had the best binding activity to NUGC4 cells that endogenously express human CLDN18.2 protein, and was clearly stronger than the reference antibody Ref.ch175.
[0157] Example 11: Detection of binding activity of anti-CLDN18.2 human mouse chimeric antibody to HEK293-hCLDN18.2 cells Flow cytometry experiments were performed using chimeric antibodies ch429, ch624, ch782, and Ref.ch175 diluted 3-fold starting from a concentration of 10 μg / ml according to the method described in Example 8. Graphs were created using GraphPad Prism 8 software fitting with MFI as the ordinate, and EC50 was calculated.
[0158] The results are shown in FIG. 5 and the table below. [Table 8]
[0159] The chimeric antibodies ch429 and ch782 of the present invention and the reference antibody Ref.ch175 can all bind to HEK293-hCLDN18.2 cells, with EC50 of 0.52 μg / ml, 0.81 μg / ml and 0.85 μg / ml, respectively, while the binding activity of ch624 is obviously weaker. Furthermore, at high concentrations, ch782 has a higher MFI binding to HEK293-hCLDN18.2 cells than Ref.ch175.
[0160] Example 12: Detection of ADCC activity of anti-CLDN18.2 human-mouse chimeric antibody against HEK293-hCLDN18.2 cells by reporter gene method The ADCC effect mediated by the antibody Fc terminus is an important indicator for evaluating the antitumor activity of antibodies. ADCC is antibody-dependent cell-mediated cytotoxicity, and its mechanism of action is that when an antibody binds to an antigen on the surface of a tumor, the antibody Fc region binds to immune effector cell receptors, mainly recognizing the Fc receptors on NK cells as targets, and directly lyses and kills tumor cells.
[0161] In this example, the ADCC biological activity of the antibody was detected by the reporter gene method, and the function of the antibody Fc effector factor was quantitatively detected by using engineered Jurkat cells that stably express the FcγRIIIa receptor as effector cells and detecting the chemiluminescent signal of luciferase using the Bio-Glo™ Luciferase Assay System kit to measure the activation of the NFAT signal pathway.
[0162] After digestion of the HEK293-hCLDN18.2 cells constructed in Example 1, 2.5 × 10 5 The cells were diluted to 6 × 10 Jurkat / NFAT-luc+FcγRIIIa cells / ml and then spread onto a white, opaque cell culture plate at 100 μl / well. After static culture at 37°C for 24 hours, the supernatant was discarded and 25 μl / well of 0.1% BSA-containing assay medium was added. 6 The antibody was diluted to 1 / mL, and a 96-well plate was taken, and 25 μl of Jurkat / NFAT-luc+FcγRIIIa cell suspension was added to each well, and 25 μL of antibody dilution solution was added to each well to a final concentration of 6 μg / mL, and the same concentration was diluted 3-fold from the same concentration, resulting in a total dilution gradient of 10. The cell plate was placed in a constant temperature incubator, and after 6 h of induction culture, the 96-well plate was placed at room temperature to equilibrate for at least 15 min, and Bio-GloTM Luciferase Assay Reagent was added to all reaction wells at 75 μL / well using a continuous pipette (the staining solution needs to be protected from light), and the reaction was allowed to proceed for 5 min at room temperature, and the plate was set in a multi-function plate reader to detect the Luminescence light signal value. The fluorescence value and antibody concentration were fitted with GraphPad Prism 8 software to create a graph and calculate the EC50.
[0163] The results are shown in FIG. 6 and the table below. [Table 9]
[0164] The results show that after gradient dilution of ch782 and the reference antibody Ref.ch175, with an effector-target ratio E:T=6:1, and incubation at 37°C for 6 h, both ch782 and Ref.ch175 can induce strong ADCC activity.
[0165] Example 13: Humanization of anti-CLDN18.2 antibody ch782 In order to reduce the immunogenicity of the antibody, and to reduce the human anti-mouse antibody (HAMA) effect caused by the administration of the antibody into the body, the suitable antibody ch782 was humanized. Specifically, humanization sequence design was performed on the sequence of the variable region of the mab782 antibody in Example 6. The amino acid sequences of the heavy and light chains were numbered according to the Kabat numbering system, and sequence homology alignment was performed using NCB Igblast (https: / / www.ncbi.nlm.nih.gov / igblast / ). The sequence of a highly homologous human-derived antibody was used as the framework, and CDR grafting of the mouse-derived antibody was performed, and some of the key amino acids in the framework region were back-mutated.
[0166] Blast was used to search for homologous sequences of the heavy chain of the 782 antibody and human germline sequences. [Table 10]
[0167] Blast was used to search for homologous sequences of the light chain of the 782 antibody and human germline sequences. [Table 11]
[0168] The FR and CDR sequences defined by Kabat in the heavy chain variable region of the 782 antibody are as follows: [Table 12]
[0169] The Kabat-defined FR and CDR sequences in the light chain variable region of the 782 antibody are as follows: [Table 13]
[0170] In the present invention, the antibody heavy chain was humanized by replacing the CDR region using the highly homologous IGHV4-61 as a template, and when transplanting the heavy chain CDR1, the CDR1 site defined by Chothia was simultaneously included, and the three sites I48M / V67I / V71R were subjected to reversion mutation to obtain hu782H1.1.
[0171] Post-translational modification analysis revealed a potential glycosylation site at the S60 site, which was mutated to S60A by means of point mutation and named hu782H1.2, and its expression was optimized by mutating the 101st amino acid V to A and named hu782 H1.2-V101A.
[0172] In the present invention, the antibody light chain was humanized by replacing the CDR region using the VκI consensus sequence as a template to obtain hu782L1, and by replacing the CDR region using IGKV4-1 as a template to obtain hu782L2. After codon optimization of the above sequences, the whole gene was synthesized and cloned into an expression vector containing heavy and light chain constant regions for expression and purification.
[0173] hu782H1.1 (SEQ ID NO: 11) QVQLQESGPGLVKPSETLSLTTCTVSGYSITSGYSWHWIRQPPGKGLEW M GYIHYSDNTNYSPSLKSR I TIS R DTSKNQFSLKLSSVTAADTAVYYCARIYYGNSFVYWGQGTLVTVSS
[0174] hu782H1.2 (SEQ ID NO: 12) QVQLQESGPGLVKPSETLSLTTCTVSGYSITSGYSWHWIRQPPGKGLEW M GYIHYSDNTNY A PSLKSR I TIS R DTSKNQFSLKLSSVTAADTAVYYCARIYYGNSFVYWGQGTLVTVSS
[0175] hu782H1.2-V101A (SEQ ID NO: 13) QVQLQESGPGLVKPSETLSLTTCTVSGYSITSGYSWHWIRQPPGKGLEW M GYIHYSDNTNYAPSLKSR I TIS R DTSKNQFSLKLSSVTAADTAVYYCARIYYGNSF A YWGQGTLVTVSS
[0176] hu782L1 (SEQ ID NO: 14) DIQMTQSPSSLSASVGDRVTITCKSSQSLLNSGNQKNYLTWYQQKPGKAPKLLIYWASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQNDYFYPYTFGQGTKVEIK
[0177] hu782L2 (SEQ ID NO: 15) DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLTWYQQKPGQPPLLIYWASTR ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQNDYFYPYTFGGGTKLEIK
[0178] Example 14: Detection of specific binding activity of humanized antibodies to CLDN18.2 Using the method for evaluating the binding activity of chimeric antibodies in the above Examples, the binding activities of the humanized antibodies to human CLDN18.1 and CLDN18.2, mouse CLDN18.1 and CLDN18.2, and NUGC4 cells were detected.
[0179] The results are shown in FIG. 7 and the table below. [Table 14]
[0180] The results showed that all humanized antibodies were able to specifically bind to human CLDN18.2, and no obvious decrease in binding activity was observed compared to the chimeric antibody ch782. Moreover, unexpectedly, the EC50 values of the four humanized antibodies for cell binding to tumor cells NUGC4 were significantly better than that of the chimeric antibody ch782.
[0181] Example 15: Detection of ADCC activity of humanized antibodies One of the main mechanisms of in vivo activity of antibodies in the present invention is ADCC functional activity, and human IgG1 antibody (hIgG1) mainly binds to FcγR via the antibody hinge region and CH2 region to exert ADCC effect. In order to enhance the ADCC activity of humanized antibodies, in this example, S239D / I332E (DE) mutations were introduced into the Fc of the humanized antibody heavy chain hu782H1.2 to enhance its affinity for FcγR, thereby achieving the purpose of enhancing ADCC. After expression and purification, the ADCC of wild-type and DE mutant human-derived antibodies was evaluated by the reporter gene method. [Table 15]
[0182] The method is as follows: According to the specific operation steps in Example 12, 2.5 × 10 target cells, HEK293-hCLDN18.2 and NUGC4 cells, were cultured in a 5% CO2 medium. 5 The cells were diluted to 6 × 10 Jurkat / NFAT-luc+FcγRIIIa cells / ml and then spread onto a white, opaque cell culture plate at 100 μl / well. After static culture at 37°C for 24 hours, the supernatant was discarded and 25 μl / well of 0.1% BSA-containing assay medium was added. 6The antibody was diluted to 1 / mL, and a 96-well plate was taken, and 25 μL of Jurkat / NFAT-luc+FcγRIIIa cell suspension was added to each well, and 25 μL of antibody dilution solution was added to each well to make the final concentration 6 μg / mL, and the same concentration was diluted 3-fold from the same concentration, resulting in a total dilution gradient of 10. The cell plate was placed in a constant temperature incubator, and after 6 h of induction culture, the 96-well plate was placed at room temperature to equilibrate for at least 15 min, and Bio-GloTM Luciferase Assay Reagent was added to all reaction wells at 75 μL / well using a continuous pipette (the staining solution needs to be protected from light), and the reaction was allowed to proceed for 5 min at room temperature, and the plate was set in a multi-function plate reader to detect the Luminescence light signal value. The fluorescence value and antibody concentration were fitted with GraphPad Prism 8 software to create a graph and calculate the EC50. [Table 16]
[0183] The results showed that against recombinant cells with high expression of human CLDN18.2, the chimeric antibody ch782 and the humanized antibodies hu782 and hu782-HV all effectively exerted ADCC activity comparable to that of the reference antibodies (EC50 was 47.64ng / ml, 64.03ng / ml, and 70.94ng / ml, respectively), and the Fc primer S239D / I332E mutation hu782-DE showed significantly improved ADCC activity (Figure 8).
[0184] Similar results were also observed in NUGC4 cells that endogenously express human CLDN18.2, and the candidate antibodies ch782 and hu782 obtained in the present invention had better ADCC activity against NUGC4 cells than the reference antibody Ref.ch175.
[0185] Then, ADCC activity was detected using NUGC4 cells stably transfected with hCLDN18.2 as target cells. The results showed that hu782-DE and hu782-HV-DE had significantly better ADCC activity than the control antibody Ref.ch175, with EC50 values of 6.87ng / ml and 11.48ng / ml, respectively (Figure 8C).
[0186] Example 16: Detection of CDC activity of humanized antibodies CDC is a complement-dependent cytotoxicity, and its mechanism of action is that the antigen-antibody mixture bound to complement finally opens holes in the cell membrane, changes the osmotic pressure of the cell, and finally leads to cell lysis. In this example, HEK293-hCLDN18.2 cells were used as target cells, complement was provided by infant rabbit complement serum, and the antibody CDC effect was detected by CCK-8 cell proliferation-toxicity detection kit.
[0187] The HEK293-hCLDN18.2 cells in Example 1 were used as target cells, and after digestion, 2.0 × 10 5 The cells were diluted to 100 μL / well and placed in a 96-well light-transmitting black culture plate, and incubated for about 4 h until the cells were completely attached to the wall. The growth medium was completely aspirated, and 50 μL / well of analysis medium was added. 50 μL / well of diluted antibody was added to the reaction well, and 50 μL of 1:15 diluted infant rabbit complement was added, so that the final volume of each well was 150 μL, the volume of the sample in each well was 1 / 3 of the total volume, the initial concentration was 3 times that of the target, and the target concentration was from 6 μg / mL. The cell plate was placed in a constant temperature incubator, and after 12 h of induction culture, the medium was aspirated, 100 μL / well of fresh analysis medium was added, and 10 μL / well of CCK-8 solution was added at room temperature, and the plate was placed in a 5% CO2 incubator and incubated at 37 °C for 4 h in the dark. The plate was set in a multi-function plate reader and the OD value was detected at a wavelength of 450 nm. A graph was created by fitting using GraphPad Prism 8 software, and the EC50 value was calculated.
[0188] The results are shown in the table below. [Table 17]
[0189] The results showed that ch782, hu782, and hu782HV of the present invention were all able to induce CDC effects on HEK293-hCLDN18.2 cells equivalent to that of the reference antibody Ref.ch175 (EC50 was 30.9 ng / ml, 49.46 ng / ml, 47.58 ng / ml, and 40.89 ng / ml, respectively).
[0190] Example 17 Detection of the proliferation inhibitory effect of humanized antibodies on HEK293-hCLDN18.2 cells HEK293-hCLDN18.2 cells were harvested during logarithmic growth. After digestion and counting of the target cells, the cells were diluted to 1.0 × 10 5 The antibody was diluted to 100 μL / well and placed on a 96-well light-transmitting black culture plate at a volume of 100 μL / well, and cultured for about 4 hours until the cells were completely attached to the wall. The diluted antibody was placed in the reaction well at 100 μL / well, and the final volume of each well was 200 μL. The 96-well plate was placed in a 5% CO2 incubator and cultured for 96 hours at 37°C for induction. The medium was then sucked up, and fresh analysis medium was placed at 100 μL / well. CCK-8 solution was placed at room temperature at 10 μL / well, and the plate was placed in a 5% CO2 incubator and reacted for 4 hours at 37°C away from light. The plate was set in a multi-function plate reader and the OD value was detected at a wavelength of 450 nm. The result was cell proliferation inhibition rate = 1-(OD450 抗体 / OD450 ブランク ) was calculated.
[0191] The results showed that the antibody hu782 of the present invention had a better proliferation inhibitory effect on target cells at a low concentration (1 μg / ml) than the reference antibody Ref. ch175 at a high concentration (30 μg / ml) (18.3% vs. 7.3%), and showed a dose-dependent tendency in which the proliferation inhibitory effect became stronger as the antibody concentration increased. At a concentration of 30 μg / ml, the cell proliferation inhibition rates of ch782, hu782, and hu782-HV reached 67.8%, 76%, and 63.2%, respectively, which were significantly better than the reference antibody Ref. ch175.
[0192] Example 18: Analysis of the binding site of the humanized antibody to the hCLDN18.2 protein In order to explore the important amino acid site of the antibody of the present invention that binds to hCLDN18.2 protein but not to hCLDN18.1 protein, in this embodiment, the amino acid difference site between hCLDN18.2 ECL1 and hCLDN18.1 ECL1 and the amino acid around it were mutated to alanine in the pEFGP-N2- hCLDN18.2 plasmid constructed in Example 1 by point mutation, where A42 was mutated to the allelic amino acid S in hCLDN18.1 ECL1 (Q29A, S31A, N37A, A42S, N45A, Q47A, G48A, S52A, E56A, G65A, L69A, G71A). The mutated plasmid and wild-type plasmid were transfected into 293Fv cells respectively by the method in Example 1, and after 48 hours, the cells were taken and detected by flow cytometry.
[0193] hu782, Ref.ch175 and isotype control (IsotypecontrolhIgG1) were diluted to 10μg / ml and incubated with the above transfected cells for 1 hour on ice, washed twice with FACS buffer, added sheep anti-mouse IgG-PE secondary antibody diluted at 1:400, incubated on ice for 45 min, washed twice with FACS buffer, added 300μl of loading buffer, transferred to BD flow cytometry tubes and analyzed by BD FACS calibur. Median fluorescence intensity (MFI) results were analyzed by Flowjo software, and the results were judged as important amino acid sites affecting antibody binding when the MFI of the transfected cells after mutation was reduced by 50% or more compared to the wild type.
[0194] The results show that the A42S, N45A, and E56A mutations of the present invention have a large effect on the binding of the reference antibody Ref.ch175, but the A42S mutation has no effect on the binding of hu782, the N45A mutation has a small effect on the binding of hu782, and the E56A mutation has a large effect on the binding of hu782, as shown in Figure 11. At the same time, the present invention unexpectedly found that when the similar amino acid site G48A of hCLDN18.2 ECL1 and hCLDN18.1 ECL1 was mutated, neither the reference antibody Ref.ch175 nor hu782 could bind.
[0195] Example 19: Evaluation of in vivo activity of humanized antibodies In this example, a CDX animal model was established by subcutaneously implanting tumor cells into BALB / c nude mice, and the in vivo efficacy of the humanized antibody was evaluated.
[0196] The NUGC4-hCLDN18.2 stable transfected cell line constructed by the method of Example 1 was used for expansion culture. 4-6 week old female SPF BALB / c nude mice were selected and after 3-4 days of adaptation breeding, tumor inoculation was prepared. The recombinant NUGC4-hCLDN18.2 cells in the logarithmic growth phase were digested, washed twice with serum-free 1640 medium, and then cultured at 2.5 × 107 The mice were then injected subcutaneously in the right armpit with 0.2 ml of the solution, totaling 5 × 10 6 One week after inoculation, tumors were 70-100 mm 3 When the mice reached 100 mm Hg, they were randomly divided into groups of 6 mice per group. The blank model group was the IgG1 isotype control. The experimental group was administered with a dose of 10 mg / kg, twice a week, by alternating intraperitoneal and intravenous injections. The tumor volume and mouse body weight were recorded before each administration.
[0197] Tumor volume was calculated as V (mm 3 )=(W 2 x L) / 2, where W is the shortest diameter of the tumor near the midline and L is the longest diameter of the tumor near the midline. Tumor volume 2000 mm 3 Mice were sacrificed by cervical dislocation when the tumor volume exceeded 100 mg / kg / day, or when body weight loss exceeded 20%, or when interference with vital physiological functions or tumor ulceration or necrosis were observed.
[0198] The formula for calculating the tumor inhibition rate (TGI) is as follows:
number
[0199] In the NUGC4-hCLDN18.2 mouse subcutaneous tumor model, the anti-tumor growth activity of the humanized antibody of the present invention and its mutants was observed, and both showed some degree of efficacy. At the end of the study, the tumor volumes of each group are shown in the table below. [Table 18]
[0200] In the humanized antibody hu782 and its mutant hu782-HV, hu782-DE groups, the tumor inhibition rates were all significantly higher than those in the Ref.ch175 group, and in particular, in the hu782 and its ADCC-enhancing mutant antibody hu782-DE groups, the tumor inhibition rates reached 62.88% and 65.05%, respectively. In addition, complete regression of tumors was observed in one mouse out of six mice in the hu782 group, and complete regression of tumors was observed in two mice out of six mice in the hu782-DE group, but this phenomenon was not observed in either the Ref.ch175 group or the hu782-HV group.
[0201] The above results demonstrate that the antibodies of the present invention (especially the humanized antibodies) have significantly better in vivo efficacy than the reference antibody Ref. ch175.
[0202] All documents related to the present invention are incorporated herein by reference as if each document were incorporated individually. After reading the above content of the present invention, it will be understood that those skilled in the art can make various changes and modifications to the present invention, and that equivalent forms thereof are within the scope of the claims of the present invention.
Claims
1. The heavy chain variable region of the anti-human CLDN18.2 antibody comprises the following three complementarity determining regions CDR: (1) a complementarity determining region CDR1, the amino acid sequence of which is shown in SEQ ID NO:3; (2) a complementarity determining region CDR2 having an amino acid sequence as set forth in SEQ ID NO: 4 or 16; and (3) A complementarity determining region (CDR3) having an amino acid sequence represented by SEQ ID NO: 5 or 17. The heavy chain variable region comprising:
2. An anti-human CLDN18.2 antibody heavy chain, characterized in that it has the heavy chain variable region of the antibody described in claim 1.
3. The light chain variable region of the anti-human CLDN18.2 antibody comprises the following three complementarity determining regions CDR': (1) a complementarity determining region CDR1′, the amino acid sequence of which is shown in SEQ ID NO:8; (2) a complementarity determining region CDR2', the amino acid sequence of which is set forth in SEQ ID NO:9; and (3) A complementarity determining region CDR3', the amino acid sequence of which is shown in SEQ ID NO:
10. The light chain variable region comprising:
4. An anti-human CLDN18.2 antibody light chain, characterized in that it has the light chain variable region of the antibody described in claim 3.
5. An anti-human CLDN18.2 antibody, (1) The heavy chain variable region according to claim 1, and / or (2) The light chain variable region according to claim 3. or having a heavy chain according to claim 2 and / or a light chain according to claim 4.
6. The antibody of claim 5, characterized in that it has a heavy chain variable region shown in SEQ ID NO: 1, 11, 12, or 13; and / or a light chain variable region shown in SEQ ID NO: 6, 14, or 15.
7. A recombinant protein comprising: (i) a heavy chain variable region according to claim 1, a heavy chain according to claim 2, a light chain variable region according to claim 3, a light chain according to claim 4, or an antibody according to claim 5, and (ii) an optional tag sequence to aid in expression and / or purification; The protein, characterized in that it has the following structure:
8. 1. An antibody formulation comprising: (a) an anti-human CLDN18.2 antibody according to claim 5, and (b) A vehicle containing a buffer, sterile water, and an optional surfactant. The antibody formulation comprising:
9. A CAR construct, characterized in that the scFv fragment of the antigen binding region of the CAR construct is a binding region that specifically binds to CLDN18.2, and the scFv has a heavy chain variable region described in claim 1 and a light chain variable region described in claim 3.
10. A recombinant immune cell, characterized in that it expresses an exogenous CAR construct according to claim 9.
11. 1. An antibody-drug conjugate comprising: (a) an antibody moiety selected from the group consisting of a heavy chain variable region of claim 1, a heavy chain of claim 2, a light chain variable region of claim 3, a light chain of claim 4, or an antibody of claim 5, or a combination thereof; (b) a conjugation moiety conjugated to said antibody moiety, said conjugation moiety being selected from the group consisting of a detectable marker, a drug, a toxin, a cytokine, a radionuclide, an enzyme, or a combination thereof; The antibody-drug conjugate according to claim 1,
12. 13. Use of an active ingredient, the active ingredient being selected from the group consisting of a heavy chain variable region according to claim 1, a heavy chain according to claim 2, a light chain variable region according to claim 3, a light chain according to claim 4, or an antibody according to claim 5, a recombinant protein according to claim 7, an immune cell according to claim 10, an antibody-drug conjugate according to claim 11, or a combination thereof, the active ingredient being: (a) production of detection reagents or kits; (b) the manufacture of a drug or preparation for preventing and / or treating a CLDN18.2-related disease; and / or (c) Manufacture of drugs or preparations for preventing and / or treating cancer or tumors The above-mentioned use, characterized in that it is used for the purpose of:
13. 1. A pharmaceutical composition comprising: (i) an active ingredient selected from the group consisting of a heavy chain variable region of claim 1, a heavy chain of claim 2, a light chain variable region of claim 3, a light chain of claim 4, or an antibody of claim 5, a recombinant protein of claim 7, an immune cell of claim 10, an antibody-drug conjugate of claim 11, or a combination thereof; (ii) a pharma- ceutically acceptable carrier; The composition comprising:
14. A polypeptide selected from the group consisting of: (1) A heavy chain variable region according to claim 1, a heavy chain according to claim 2, a light chain variable region according to claim 3, a light chain according to claim 4, or an antibody according to claim 5; or (2) A recombinant protein according to claim 7; and / or (3) The CAR construct according to claim 9. A polynucleotide encoding the
15. A vector comprising the polynucleotide of claim 14.
16. A genetically engineered host cell, characterized in that the host cell contains the vector of claim 15 or has the polynucleotide of claim 14 integrated into its genome.
17. A method for detecting CLDN18.2 protein in a sample in vitro (including diagnostic or non-diagnostic) comprising the steps of: (1) contacting the sample with the antibody of claim 5 in vitro; (2) Detecting whether an antigen-antibody complex is formed, where the formation of the complex indicates the presence of CLDN18.2 protein in the sample. The method according to claim 1, further comprising:
18. A detection plate comprising a substrate (support plate) and a test strip, characterized in that the test strip contains the antibody of claim 5 or the antibody-drug complex of claim 11.
19. A kit comprising: (1) a first container containing the antibody according to claim 5, and / or (2) A second container containing a secondary antibody against the antibody according to claim 5. or comprising the detection plate of claim 18.
20. A method for preventing and / or treating a CLDN18.2-related disease, comprising administering to a subject in need thereof an antibody according to claim 5, an antibody-drug conjugate of said antibody, or a CAR-T cell expressing said antibody, or a combination thereof.
Citation Information
Patent Citations
Monoclonal antibodies against claudin-18 for treatment of cancer
US8168427B2
Antibody against claudin 18a2 and use thereof
WO2020228806A1
